Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
June 25, 2007
- Hemorrhoid Recurrence Rate 16% 1 Year after Zione Treatment
June 25, 2007
- 14 New Kit/Report Products Included in NHI Price List
June 25, 2007
- Teijin Pharma Aims at Entering Home Health Care Business in US, Europe: Mr Ohyagi
June 25, 2007
- JPMA Explains Its Drug Pricing
June 25, 2007
- US Gov't Confirms Opposition to Yearly Revisions of NHI Prices: Policy Initiatives
June 25, 2007
- Price Gaps between Original Drugs and Generics too Large: Mr Mukai of MOF
June 25, 2007
- GENERIC NEWS IN BRIEF
June 18, 2007
- WG Inaugurated to Predict Demand & Supply for Pharmacists
June 18, 2007
- 28 Drugs (13 APIs) Included in NHI Price List
June 18, 2007
- Sales of 23 TSE Section 1 Companies Up 2.2%
June 18, 2007
- 77 Applications for New Drugs Approved in FY2006: PMDA
June 18, 2007
- Reconsider Insurance Coverage of Long-listed Original Drugs, OTC Drug-Like Ethical Drugs: Council
June 18, 2007
- REGULATORY NEWS IN BRIEF
June 18, 2007
- R&D NEWS IN BRIEF
June 18, 2007
- Takeda Looks for Alliance, Acquisition Opportunities: President Hasegawa
June 18, 2007
- Five Medical Devices Recommended for Priority Review
June 18, 2007
- SURVEY／Metabolic Syndrome Affects 19 Mil. Japanese
June 18, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 18, 2007
- Bulk Buying by Sum Value Should Be Eliminated: FJPWA President
June 18, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…